IP Library Assignment 052920/0631
Patent Assignment
Reel/Frame 052920/0631

Release of Security Interest

Recorded: 2020-06-12 Pages: 9
Assignor
Assignee
HUMANIGEN, INC.
533 AIRPORT BLVD., SUITE 400, BURLINGAME, CALIFORNIA, 94010
Covered Properties (22)
EPHA3 Antibodies for the Treatment of Pulmonary Fibrosis
Circularly Permutated, Interaction-Activated Proteins
Patent: 7,544,477 →
Application: 09/764,163 →
Publication: US 2003/0165825
Detection of Molecular Interactions by Beta-Lactamase Reporter Fragment Complementation
Patent: 8,148,110 →
Application: 10/330,811 →
Publication: US 2003/0175836
Antibody Specificity Transfer Using Minimal Essential Binding Determinants
Patent: 7,981,843 →
Application: 11/040,159 →
Publication: US 2005/0255552
Secretion of Antibodies Without Signal Peptides from Bacteria
Patent: 8,211,648 →
Application: 11/273,906 →
Publication: US 2007/0020685
EphA3 Antibodies for the Treatment of Solid Tumors
Patent: 8,637,016 →
Application: 12/045,589 →
Publication: US 2008/0286272
Antibodies to the Pcrv Antigen of Pseudomonas Aeruginosa
Patent: 8,044,181 →
Application: 12/325,806 →
Publication: US 2009/0191186
Methods of Treating Heart Failure Using an Anti-Gm-Csf Antibody
Patent: 8,075,885 →
Application: 12/419,991 →
Publication: US 2009/0263387
Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor
Patent: 8,168,183 →
Application: 12/431,661 →
Publication: US 2009/0274706
Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
Patent: 8,834,870 →
Application: 12/718,768 →
Publication: US 2010/0226930
Antibodies to EPHA3
Patent: 8,664,365 →
Application: 12/904,953 →
Publication: US 2011/0123549
Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor
Patent: 9,017,674 →
Application: 13/460,151 →
Publication: US 2012/0213776
Anti-EMR1 Antibodies
Patent: 9,045,539 →
Application: 13/480,937 →
Publication: US 2013/0064826
Secretion of antibodies without signal peptides from bacteria
Patent: 9,127,046 →
Application: 13/506,653 →
Publication: US 2012/0309055
Methods of Treating Hematological Proliferative Disorders by Targeting EPHA3 Expressed on Aberrant Vasculature in Bone Marrow
Patent: 9,109,032 →
Application: 13/571,827 →
Publication: US 2013/0039907
Antibodies to EPHA3
Patent: 9,290,571 →
Application: 14/143,427 →
Publication: US 2014/0120114
Immunoglobulin Variable Region Cassette Exchange
Application: 14/968,709 →
Publication: US 2016/0102152
Methods of Treating Immunotherapy-Related Toxicity Using a Gm-Csf Antagonist
Application: 16/149,346 →
Publication: US 2019/0194343
Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
Application: 16/204,220 →
Publication: US 2019/0284271
Method of Reducing Tumor Relapse Rate in Immunotherapy by Administration of Lenzilumab
Application: 16/248,762 →
Publication: US 2019/0338023
Methods of Treating Cart-T Cell Therapy-Induced Neuroinflammation Using a Gm-Csf Antagonist
Application: 16/283,694 →
Publication: US 2019/0322735
EPHA3 Antibodies for the Treatment of Pulmonary Fibrosis
Application: 16/333,094 →
Publication: US 2019/0270821
Related Assignments (16)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 26, 2012
From: YARRANTON, GEOFFREY T.; PALATH, VARGHESE; BEBBINGTON, CHRISTOPHER R.; BAER, MARK
To: KALOBIOS PHARMACEUTICALS, INC.
Reel/Frame 029196/0484 →
Assignment of Assignor's Interest Nov 8, 2012
From: LUEHRSEN, KENNETH; BAER, MARK; BEBBINGTON, CHRISTOPHER R.; MARTINEZ, DAVID
To: KALOBIOS PHARMACEUTICALS, INC.
Reel/Frame 029267/0156 →
Assignment of Assignor's Interest Jun 26, 2015
From: BEBBINGTON, CHRISTOPHER R.; LUEHRSEN, KENNETH; YARRANTON, GEOFFREY T.
To: KALOBIOS PHARMACEUTICALS, INC.
Reel/Frame 035918/0208 →
Assignment of Assignor's Interest Feb 29, 2016
From: LUEHRSEN, KENNETH; MARTINEZ, DAVID; YI, CHRISTINA; BEBBINGTON, CHRISTOPHER R.
To: KALOBIOS PHARMACEUTICALS, INC.
Reel/Frame 037854/0777 →
Security Interest May 23, 2016
From: KALOBIOS PHARMACEUTICALS, INC.
To: BLACK HORSE CAPITAL, LP
Reel/Frame 038788/0266 →
Security Interest Dec 22, 2016
From: KALOBIOS PHARAMECUTICALS, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 041181/0605 →
Change of Name Nov 6, 2017
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 044377/0915 →
Change of Name Nov 6, 2017
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 044767/0814 →
Release of Security Interest Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045788/0148 →
Release of Security Interest Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045855/0533 →
Assignment of Assignor's Interest Oct 5, 2018
From: DURRANT, CAMERON; CHAPPELL, DALE
To: HUMANIGEN, INC.
Reel/Frame 047083/0426 →
Assignment of Assignor's Interest Mar 15, 2019
From: BEBBINGTON, CHRISTOPHER ROBERT; LUEHRSEN, KENNETH R.; YARRANTON, GEOFFREY T.
To: HUMANIGEN, INC.
Reel/Frame 048614/0012 →
Security Interest Jul 16, 2019
From: HUMANIGEN, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 049769/0067 →
Change of Name May 15, 2020
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 052679/0552 →
Change of Name Jun 5, 2020
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 052858/0975 →
Change of Name Dec 29, 2020
From: KALOBIOS PHARMACEUTICALS, INC.
To: HUMANIGEN, INC.
Reel/Frame 054869/0599 →